Latest Diabetic Neuropathy News

Page 1 of 1

Zelira’s ZLT-L-007 Outperforms Lyrica, Strengthens Funding for HOPE® 1 Trials

Zelira Therapeutics reports promising diabetic neuropathy study results with ZLT-L-007 surpassing Lyrica, while converting $3.25 million in notes to equity to bolster HOPE® 1 clinical development.

Ada Torres

30 July 2025

Zelira’s ZLT-L-007 Surpasses Lyrica® in Diabetic Neuropathy Pain Relief

Zelira Therapeutics has published full results from a Phase I study showing its cannabinoid-based therapy ZLT-L-007 significantly outperforms Lyrica® in managing diabetic neuropathy pain and related symptoms.

Ada Torres

22 May 2025